Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ATXS)

Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry

Business Wire January 5, 2017

Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight

Business Wire January 4, 2017

Catabasis Pharmaceuticals Provides Edasalonexent and Rare Disease Pipeline Updates at Investor Day

Business Wire November 17, 2016

Catabasis Pharmaceuticals, Inc. (Nasdaq: CATB) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire November 16, 2016

Catabasis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights

Business Wire November 10, 2016

Catabasis Pharmaceuticals to Host Investor Day in New York City on November 17

Business Wire November 3, 2016

Catabasis Pharmaceuticals Presents Positive Data for CAT-5571, a Novel Activator of Autophagy, as a Potential Oral Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference

Business Wire October 27, 2016

Catabasis Pharmaceuticals to Report Third Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, November 10

Business Wire October 26, 2016

Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference

Business Wire October 20, 2016

Catabasis Pharmaceuticals to Present the MoveDMD® Trial of Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy for DMD, at the American Neurological Association’s 2016 Annual Meeting

Business Wire October 11, 2016

Catabasis Pharmaceuticals Presents Positive Data from Part A of the MoveDMD® Trial of Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy for DMD, at the World Muscle Society Congress

Business Wire October 6, 2016

Catabasis Pharmaceuticals Announces Promotion of Andrew Nichols, Ph.D. to Chief Scientific Officer and Angelika Fretzen to Senior Vice President of Product Development

Business Wire October 5, 2016

Catabasis Pharmaceuticals Completes Target Enrollment for Part B of the MoveDMD® Trial, a Phase 2 Trial of Edasalonexent (CAT-1004) for the Potential Treatment of Duchenne Muscular Dystrophy

Business Wire October 4, 2016

16 Stocks Moving In Friday's Pre-Market Session

Benzinga.com September 30, 2016

Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher

Benzinga.com September 29, 2016

Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide

Benzinga.com September 29, 2016

Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations

Benzinga.com September 29, 2016

Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy

Business Wire September 29, 2016

Catabasis Pharmaceuticals Announces Closing of $11.5 Million Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

Business Wire September 28, 2016

Catabasis Pharmaceuticals Announces Pricing of $10 Million Offering of Common Stock

Business Wire September 23, 2016